《慢加急性肝衰竭诊治指南（2025年版）》解读

徐曼曼; 邹怀宾; 段钟平; 韩涛; 陈煜

doi:10.12449/JCH250508

《慢加急性肝衰竭诊治指南（2025年版）》解读

DOI: 10.12449/JCH250508

徐曼曼¹,
邹怀宾¹,
段钟平^1, , ,,
韩涛^2, , ,,
陈煜^1, , ,

1.
首都医科大学附属北京佑安医院肝病中心四科，北京 100069
2.
南开大学第一附属医院（天津市人民医院）消化科，天津 300121

基金项目:

首都卫生发展科研专项项目 (CFH2024-1-2181);

高层次公共卫生技术人才建设项目（学科带头人-01-12） (Discipline leader-01-12);

北京市医院管理中心“登峰”计划专项 (DFL20221501);

国家重点研发计划项目 (2022YFC2304402)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：徐曼曼、邹怀宾负责撰写论文；段钟平、韩涛负责修改论文并提出指导性建议；陈煜负责拟定写作思路，指导撰写文章并最后定稿。徐曼曼、邹怀宾为共同第一作者。

详细信息

通信作者:
段钟平， duan@ccmu.edu.cn （ORCID： 0000-0002-8455-0426）

韩涛， hantaomd@126.com （ORCID： 0000-0003-4216-6968）

陈煜， chybeyond1071@ccmu.edu.cn （ORCID： 0000-0003-1906-7486）

计量
- 文章访问数: 1274
- HTML全文浏览量: 49
- PDF下载量: 119
- 被引次数: 0
出版历程
- 收稿日期: 2025-05-01
- 录用日期: 2025-05-10
- 出版日期: 2025-05-25

Interpretation of guideline for diagnosis and treatment of acute-on-chronic liver failure （2025 edition）

Manman XU¹,
Huaibin ZOU¹,
Zhongping DUAN^{1
, ,
,},
Tao HAN^{2
, ,
,},
Yu CHEN^{1
, ,
,}

1.
Fourth Department of Liver Disease Center，Beijing YouAn Hospital，Capital Medical University，Beijing 100069，China
2.
Department of Gastroenterology，The First Affiliated Hospital of Nankai University （Tianjin People’s Hospital），Tianjin 300121，China

Research funding:

Capital’s Funds for Health Improvement and Research (CFH2024-1-2181);

Construction Project of High-level Technology Talents in Public Health (Discipline leader-01-12);

Beijing Hospitals Authority’‍s Ascent Plan (DFL20221501);

National Key Research and Development Program of China (2022YFC2304402)

More Information

Corresponding author: DUAN Zhongping， duan@ccmu.edu.cn （ORCID： 0000-0002-8455-0426）; HAN Tao， hantaomd@126.com （ORCID： 0000-0003-4216-6968）; CHEN Yu， chybeyond1071@ccmu.edu.cn （ORCID： 0000-0003-1906-7486）

摘要

摘要: 2025年，中华医学会肝病学分会重型肝病与人工肝学组和中华医学会肝病学分会终末期肝病及营养再生学组，组织国内有关专家联合编写了我国首部慢加急性肝衰竭诊治指南。该指南依据国内外最新研究成果和临床实践经验，首次提出较为统一的慢加急性肝衰竭定义，并针对其诊断、治疗与管理提出指导性建议。本文对指南要点进行解读，旨在为慢加急性肝衰竭的规范化诊疗提供参考。
- 慢加急性肝功能衰竭 /
- 诊断 /
- 治疗学 /
- 诊疗准则（‍主题‍）
Abstract: In 2025， Severe Liver Disease and Artificial Liver Group and Nutrition and Regeneration in End-Stage Liver Disease Group of Chinese Society of Hepatology， Chinese Medical Association， convened a panel of national experts to jointly develop China’s first guideline for the diagnosis and treatment of acute-on-chronic liver failure （ACLF）. Based on the latest research findings and clinical practice in China and globally， this guideline establishes a standardized definition of ACLF and provide recommendations for its diagnosis， treatment， and clinical management. This article gives an interpretation of the key points in the guideline， in order to provide a reference for standardized diagnosis and treatment of ACLF.
- Acute-On-Chronic Liver Failure /
- Diagnosis /
- Therapeutics /
- Practice Guidelines as Topic

HTML全文

参考文献(59)

[1]	BR VK, SARIN SK. Acute-on-chronic liver failure: Terminology, mechanisms and management[J]. Clin Mol Hepatol, 2023, 29( 3): 670- 689. DOI: 10.3350/cmh.2022.0103.
[2]	AGGARWAL A, BISWAS S, ARORA U, et al. Definitions, etiologies, and outcomes of acute on chronic liver failure: A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2024, 22( 11): 2199- 2210. e 25. DOI: 10.1016/j.cgh.2024.04.018.
[3]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure[J]. Chin J Clin Infect Dis, 2008, 1( 1): 47- 53. DOI: 10.3760/cma.j.issn.1674-2397.2008.01.014. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病人工肝学组. 肝衰竭诊疗指南[J]. 中华临床感染病杂志, 2008, 1( 1): 47- 53. DOI: 10.3760/cma.j.issn.1674-2397.2008.01.014.
[4]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2012)[J]. Chin J Clin Infect Dis, 2012, 5( 6): 321- 327. DOI: 10.3760/cma.j.issn.1674-2397.2012.06.001. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2012年版)[J]. 中华临床感染病杂志, 2012, 5( 6): 321- 327. DOI: 10.3760/cma.j.issn.1674-2397.2012.06.001.
[5]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
[6]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2024 version)[J]. J Clin Hepatol, 2024, 40( 12): 2371- 2387. DOI: 10.12449/JCH241206. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 12): 2371- 2387. DOI: 10.12449/JCH241206.
[7]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Nutrition and Regeneration in End-Stage Liver Disease Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. Chin J Hepatol, 2025, 33( 4): 329- 339. DOI: 10.3760/cma.j.cn501113-20250312-00089. 中华医学会肝病学分会重型肝病与人工肝学组, 中华医学会肝病学分会终末期肝病营养与再生学组. 慢加急性肝衰竭诊治指南(2025年版)[J]. 中华肝脏病杂志, 2025, 33( 4): 329- 339. DOI: 10.3760/cma.j.cn501113-20250312-00089.
[8]	OHNISHI H, SUGIHARA J, MORIWAKI H, et al. Acute-on-chronic liver failure[J]. Ryoikibetsu Shokogun Shirizu, 1995( 7): 217- 219.
[9]	SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver(APASL): An update[J]. Hepatol Int, 2019, 13( 4): 353- 390. DOI: 10.1007/s12072-019-09946-3.
[10]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines on acute-on-chronic liver failure[J]. J Hepatol, 2023, 79( 2): 461- 491. DOI: 10.1016/j.jhep.2023.04.021.
[11]	BAJAJ JS, O’LEARY JG, REDDY KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures[J]. Hepatology, 2014, 60( 1): 250- 256. DOI: 10.1002/hep.27077.
[12]	BAJAJ JS, O’LEARY JG, LAI JC, et al. Acute-on-chronic liver failure clinical guidelines[J]. Am J Gastroenterol, 2022, 117( 2): 225- 252. DOI: 10.14309/ajg.0000000000001595.
[13]	KARVELLAS CJ, BAJAJ JS, KAMATH PS, et al. AASLD Practice Guidance on acute-on-chronic liver failure and the management of critically ill patients with cirrhosis[J]. Hepatology, 2024, 79( 6): 1463- 1502. DOI: 10.1097/HEP.0000000000000671.
[14]	CHOUDHURY A, KULKARNI AV, ARORA V, et al. Acute-on-chronic liver failure(ACLF): The‘Kyoto consensus’-steps from Asia[J]. Hepatol Int, 2025, 19( 1): 1- 69. DOI: 10.1007/s12072-024-10773-4.
[15]	CLÀRIA J, ARROYO V, MOREAU R. Roles of systemic inflammatory and metabolic responses in the pathophysiology of acute-on-chronic liver failure[J]. JHEP Rep, 2023, 5( 9): 100807. DOI: 10.1016/j.jhepr.2023.100807.
[16]	ENGELMANN C, CLÀRIA J, SZABO G, et al. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction[J]. J Hepatol, 2021, 75( Suppl 1): S49- S66. DOI: 10.1016/j.jhep.2021.01.002.
[17]	SARIN SK, KEDARISETTY CK, ABBAS Z, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the Study of the Liver(APASL) 2014[J]. Hepatol Int, 2014, 8( 4): 453- 471. DOI: 10.1007/s12072-014-9580-2.
[18]	XU MM, LI SS, YANG YR, et al. Epidemiological characteristics of inpatients with liver failure at the Beijing You’an Hospital from 2012 to 2021[J]. Chin J Hepatol, 2024, 32( 1): 49- 57. DOI: 10.3760/cma.j.cn501113-20220824-00433. 徐曼曼, 李珊珊, 杨颜榕, 等. 2012至2021年北京佑安医院肝衰竭住院患者流行病学特征[J]. 中华肝脏病杂志, 2024, 32( 1): 49- 57. DOI: 10.3760/cma.j.cn501113-20220824-00433.
[19]	XU MM, CHEN Y. New perspectives in the definition and classification of acute-on-chronic liver failure[J]. Chin Med J(Engl), 2024, 137( 21): 2521- 2525. DOI: 10.1097/CM9.0000000000003289.
[20]	XU MM, KONG M, YU PF, et al. Clinical course and outcome patterns of acute-on-chronic liver failure: A multicenter retrospective cohort study[J]. J Clin Transl Hepatol, 2021, 9( 5): 626- 634. DOI: 10.14218/JCTH.2020.00179.
[21]	SCHWARZ M, SIMBRUNNER B, JACHS M, et al. High histamine levels are associated with acute-on-chronic liver failure and liver-related death in patients with advanced chronic liver disease[J]. Liver Int, 2024, 44( 11): 2904- 2914. DOI: 10.1111/liv.16056.
[22]	MO RD, ZHANG ZL, ZHOU YM, et al. A new prognostic model based on serum apolipoprotein AI in patients with HBV-ACLF and acutely decompensated liver cirrhosis[J]. Lipids Health Dis, 2025, 24( 1): 35. DOI: 10.1186/s12944-025-02434-8.
[23]	ZHANG Y, TAN WT, WANG XB, et al. Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes[J]. J Hepatol, 2023, 79( 5): 1159- 1171. DOI: 10.1016/j.jhep.2023.07.011.
[24]	HU CH, JIANG N, ZHENG J, et al. Liver volume based prediction model for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. J Hepatobiliary Pancreat Sci, 2022, 29( 12): 1253- 1263. DOI: 10.1002/jhbp.1112.
[25]	KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33( 2): 464- 470. DOI: 10.1053/jhep.2001.22172.
[26]	KIM WR, BIGGINS SW, KREMERS WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list[J]. N Engl J Med, 2008, 359( 10): 1018- 1026. DOI: 10.1056/NEJMoa0801209.
[27]	JALAN R, SALIBA F, PAVESI M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure[J]. J Hepatol, 2014, 61( 5): 1038- 1047. DOI: 10.1016/j.jhep.2014.06.012.
[28]	LI JQ, LIANG X, YOU SL, et al. Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. J Hepatol, 2021, 75( 5): 1104- 1115. DOI: 10.1016/j.jhep.2021.05.026.
[29]	CHOUDHURY A, JINDAL A, MAIWALL R, et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure(ACLF): Comparison of APASL ACLF research consortium(AARC) and CLIF-SOFA models[J]. Hepatol Int, 2017, 11( 5): 461- 471. DOI: 10.1007/s12072-017-9816-z.
[30]	O’LEARY JG, REDDY KR, GARCIA-TSAO G, et al. NACSELD acute-on-chronic liver failure(NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis[J]. Hepatology, 2018, 67( 6): 2367- 2374. DOI: 10.1002/hep.29773.
[31]	GUSTOT T, FERNANDEZ J, GARCIA E, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis[J]. Hepatology, 2015, 62( 1): 243- 252. DOI: 10.1002/hep.27849.
[32]	YU ZJ, ZHANG Y, CAO YY, et al. A dynamic prediction model for prognosis of acute-on-chronic liver failure based on the trend of clinical indicators[J]. Sci Rep, 2021, 11( 1): 1810. DOI: 10.1038/s41598-021-81431-0.
[33]	MENG QH, HOU W, YU HW, et al. Resting energy expenditure and substrate metabolism in patients with acute-on-chronic hepatitis B liver failure[J]. J Clin Gastroenterol, 2011, 45( 5): 456- 461. DOI: 10.1097/MCG.0b013e31820f7f02.
[34]	CHEUNG K, LEE SS, RAMAN M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies[J]. Clin Gastroenterol Hepatol, 2012, 10( 2): 117- 125. DOI: 10.1016/j.cgh.2011.08.016.
[35]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association. Clinical guidelines on nutrition in end-stage liver disease[J]. J Clin Hepatol, 2019, 35( 6): 1222- 1230. DOI: 10.3969/j.issn.1001-5256.2019.06.010. 中华医学会肝病学分会, 中华医学会消化病学分会. 终末期肝病临床营养指南[J]. 临床肝胆病杂志, 2019, 35( 6): 1222- 1230. DOI: 10.3969/j.issn.1001-5256.2019.06.010.
[36]	YAO J, ZHOU XS, WANG H, et al. Persistently increased resting energy expenditure predicts short-term mortality in patients with acute-on-chronic liver failure[J]. Ann Nutr Metab, 2018, 73( 1): 2- 9. DOI: 10.1159/000487604.
[37]	LIU X, KONG M, HUA X, et al. Effects of an individualized nutritional intervention on the prognosis of patients with liver failure[J]. Asia Pac J Clin Nutr, 2022, 31( 2): 215- 221. DOI: 10.6133/apjcn.202206_31(2).0007.
[38]	KUMAR R, PRAKASH SS, PRIYADARSHI RN, et al. Sarcopenia in chronic liver disease: A metabolic perspective[J]. J Clin Transl Hepatol, 2022, 10( 6): 1213- 1222. DOI: 10.14218/JCTH.2022.00239.
[39]	GREGORY PB, KNAUER CM, KEMPSON RL, et al. Steroid therapy in severe viral hepatitis. A double-blind, randomized trial of methyl-prednisolone versus placebo[J]. N Engl J Med, 1976, 294( 13): 681- 687. DOI: 10.1056/NEJM197603252941301.
[40]	FUJIWARA K, YASUI S, HAGA Y, et al. Early combination therapy with corticosteroid and nucleoside analogue induces rapid resolution of inflammation in acute liver failure due to transient hepatitis B virus infection[J]. Intern Med, 2018, 57( 11): 1543- 1552. DOI: 10.2169/internalmedicine.9670-17.
[41]	ZHAO J, ZHANG JY, YU HW, et al. Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy[J]. Cell Mol Immunol, 2012, 9( 5): 417- 422. DOI: 10.1038/cmi.2011.51.
[42]	HUANG C, YU KK, ZHENG JM, et al. Steroid treatment in patients with acute-on-chronic liver failure precipitated by hepatitis B: A 10-year cohort study in a university hospital in East China[J]. J Dig Dis, 2019, 20( 1): 38- 44. DOI: 10.1111/1751-2980.12691.
[43]	JIA L, XUE R, ZHU YK, et al. The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: A prospective multi-center clinical trial[J]. BMC Med, 2020, 18( 1): 383. DOI: 10.1186/s12916-020-01814-4.
[44]	XUE R, MENG QH. The management of glucocorticoid therapy in liver failure[J]. Front Immunol, 2019, 10: 2490. DOI: 10.3389/fimmu.2019.02490.
[45]	ZACCHERINI G, WEISS E, MOREAU R. Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment[J]. JHEP Rep, 2020, 3( 1): 100176. DOI: 10.1016/j.jhepr.2020.100176.
[46]	CASULLERAS M, ZHANG IW, LÓPEZ-VICARIO C, et al. Leukocytes, systemic inflammation and immunopathology in acute-on-chronic liver failure[J]. Cells, 2020, 9( 12): 2632. DOI: 10.3390/cells9122632.
[47]	CHEN P, WANG YY, CHEN C, et al. The immunological roles in acute-on-chronic liver failure: An update[J]. Hepatobiliary Pancreat Dis Int, 2019, 18( 5): 403- 411. DOI: 10.1016/j.hbpd.2019.07.003.
[48]	XU Y, JIANG YF, LI Y. Outcomes of glucocorticoid treatment in HBVAssociated acute-on-chronic liver failure patients: A retrospective observational study[J]. Turk J Gastroenterol, 2021, 32( 5): 473- 480. DOI: 10.5152/tjg.2021.20257.
[49]	WU ZB, WANG K, MO ZS, et al. Early, short-term, low-dose glucocorticoid therapy effectively blocks progression of severe acute exacerbation of chronic hepatitis B to liver failure[J]. Clin Res Hepatol Gastroenterol, 2021, 45( 5): 101505. DOI: 10.1016/j.clinre.2020.07.010.
[50]	SHI P, ZHU WT, LIANG A, et al. Efficacy and predictive factors of glucocorticoid therapy for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Acta Gastroenterol Belg, 2022, 85( 4): 593- 600. DOI: 10.51821/85.4.10728.
[51]	Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on clinical application of artificial liver and blood purification(2022 edition)[J]. J Clin Hepatol, 2022, 38( 4): 767- 775. DOI: 10.3969/j.issn.1001-5256.2022.04.007. 中华医学会肝病学分会重型肝病与人工肝学组. 人工肝血液净化技术临床应用专家共识(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 4): 767- 775. DOI: 10.3969/j.issn.1001-5256.2022.04.007.
[52]	OCAK I. A 15-year retrospective study of supportive extracorporeal therapies including plasma exchange and continuous venovenous hemodiafiltration of 114 adults with acute liver failure awaiting liver transplantation[J]. Ann Transplant, 2023, 28: e939745. DOI: 10.12659/AOT.939745.
[53]	WANG L, XU WX, ZHU S, et al. Double plasma molecular adsorption system with sequential low-dose plasma exchange in patients with hepatitis B virus-related acute-on-chronic liver failure: A prospective study[J]. J Clin Transl Hepatol, 2023, 11( 4): 908- 917. DOI: 10.14218/JCTH.2022.00254.
[54]	XU WX, ZHU S, YANG L, et al. Safety and efficacy of double plasma molecular adsorption system with sequential low-volume plasma exchange in intermediate-stage hepatitis B virus-related acute-on-chronic liver failure[J]. J Med Virol, 2023, 95( 3): e28650. DOI: 10.1002/jmv.28650.
[55]	MAIWALL R, BAJPAI M, SINGH A, et al. Standard-volume plasma exchange improves outcomes in patients with acute liver failure: A randomized controlled trial[J]. Clin Gastroenterol Hepatol, 2022, 20( 4): e831- e854. DOI: 10.1016/j.cgh.2021.01.036.
[56]	HIRANO R, NAMAZUDA K, HIRATA N. Double filtration plasmapheresis: Review of current clinical applications[J]. Ther Apher Dial, 2021, 25( 2): 145- 151. DOI: 10.1111/1744-9987.13548.
[57]	LIU H, ZHANG Q, LIU L, et al. Effect of artificial liver support system on short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Artif Organs, 2020, 44( 10): E434- E447. DOI: 10.1111/aor.13710.
[58]	YAO J, LI S, ZHOU L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure[J]. J Clin Apher, 2019, 34( 4): 392- 398. DOI: 10.1002/jca.21690.
[59]	ZHOU L, CHEN Y. Model selection and curative effect judgment criteria for artificial liver in the treatment of liver failure[J]. Chin J Hepatol, 2022, 30( 2): 127- 130. DOI: 10.3760/cma.j.cn501113-20220108-00008. 周莉, 陈煜. 人工肝治疗肝衰竭模式选择及其疗效判断标准[J]. 中华肝脏病杂志, 2022, 30( 2): 127- 130. DOI: 10.3760/cma.j.cn501113-20220108-00008.

施引文献

资源附件(0)

访问统计

本文二维码

计量

文章访问数: 1274
HTML全文浏览量: 49
PDF下载量: 119
被引次数: 0

用微信扫码二维码

分享至好友和朋友圈

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

《慢加急性肝衰竭诊治指南（2025年版）》解读

DOI: 10.12449/JCH250508

通信作者:
段钟平， duan@ccmu.edu.cn （ORCID： 0000-0002-8455-0426）

韩涛， hantaomd@126.com （ORCID： 0000-0003-4216-6968）

陈煜， chybeyond1071@ccmu.edu.cn （ORCID： 0000-0003-1906-7486）

计量

Interpretation of guideline for diagnosis and treatment of acute-on-chronic liver failure （2025 edition）

Corresponding author: DUAN Zhongping， duan@ccmu.edu.cn （ORCID： 0000-0002-8455-0426）; HAN Tao， hantaomd@126.com （ORCID： 0000-0003-4216-6968）; CHEN Yu， chybeyond1071@ccmu.edu.cn （ORCID： 0000-0003-1906-7486）

计量

目录

留言板

《慢加急性肝衰竭诊治指南（2025年版）》解读

DOI: 10.12449/JCH250508

通信作者: 段钟平， duan@ccmu.edu.cn （ORCID： 0000-0002-8455-0426） 韩涛， hantaomd@126.com （ORCID： 0000-0003-4216-6968） 陈煜， chybeyond1071@ccmu.edu.cn （ORCID： 0000-0003-1906-7486）

计量

出版历程

Interpretation of guideline for diagnosis and treatment of acute-on-chronic liver failure （2025 edition）

Corresponding author: DUAN Zhongping， duan@ccmu.edu.cn （ORCID： 0000-0002-8455-0426）; HAN Tao， hantaomd@126.com （ORCID： 0000-0003-4216-6968）; CHEN Yu， chybeyond1071@ccmu.edu.cn （ORCID： 0000-0003-1906-7486）

计量

出版历程

目录

关于本刊

投稿指南

在线期刊

肝胆学院

指南共识

通信作者:
段钟平， duan@ccmu.edu.cn （ORCID： 0000-0002-8455-0426）

韩涛， hantaomd@126.com （ORCID： 0000-0003-4216-6968）

陈煜， chybeyond1071@ccmu.edu.cn （ORCID： 0000-0003-1906-7486）